Top

Published in:

01-11-2004 | Review Article

Beneficial and ominous aspects of the pleiotropic action of erythropoietin

Authors: Wolfgang Jelkmann, Klaus Wagner

Published in: Annals of Hematology | Issue 11/2004

Abstract

The primary function of the glycoprotein hormone erythropoietin (Epo) is to promote red cell production by inhibiting apoptosis of erythrocytic progenitors in hemopoietic tissues. However, functional Epo receptors (Epo-R) have recently been demonstrated in various nonhemopoietic tissues indicating that Epo is a more pleiotropic viability and growth factor. Herein, in vitro and in vivo effects of Epo in the brain and the cardiovascular system are reviewed. In addition, the therapeutic impact of Epo in oncology is considered, including the question of whether Epo might promote tumor growth. Convincing evidence is available that Epo acts as a neurotrophic and neuroprotective factor in the brain. Epo prevents neuronal cells from hypoxia-induced and glutamate-induced cell death. Epo-R is expressed by neurons and glia cells in specific regions of the brain. Epo supports the survival of neurons in the ischemic brain. The neuroprotective potential of Epo has already been confirmed in a clinical trial on patients with acute stroke. With respect to the vasculature, Epo acts on both endothelial and smooth muscle cells. Epo promotes angiogenesis and stimulates the production of endothelin and other vasoactive mediators. In addition, Epo-R is expressed by cardiomyocytes. The role of Epo as a myocardial protectant is at the focus of present research. Epo therapy in tumor patients is practiced primarily to maintain the hemoglobin concentration above the transfusion trigger and to reduce fatigue. In addition, increased tumor oxygenation may improve the efficacy of chemotherapy and radiotherapy. However, tumor cells often express Epo-R. Therefore, careful studies are required to fully exclude that recombinant human Epo (rHuEpo) promotes tumor growth.

Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561–3565PubMed

Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95:969–981CrossRefPubMed

Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789–1806PubMed

Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, Asano Y (2000) Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58:269–282CrossRefPubMed

Akimoto T, Kusano E, Ito C, Yanagiba S, Inoue M, Amemiya M, Ando Y, Asano Y (2001) Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens 19:193–202CrossRefPubMed

Alafaci C, Salpietro F, Grasso G, Sfacteria A, Passalacqua M, Morabito A, Tripodo E, Calapai G, Buemi M, Tomasello F (2000) Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 406:219–225CrossRefPubMed

Ammarguellat F, Llovera M, Kelly PA, Goffin V (2001) Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 284:1031–1038CrossRefPubMed

Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87:5978–5982

Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974–3978

10.

Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911–918PubMed

11.

Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103:921–926CrossRefPubMed

12.

Banerjee D, Rodriguez M, Nag M, Adamson JW (2000) Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895–1904CrossRefPubMed

13.

Barber DL, Beattie BK, Mason JM, Nguyen MHH, Yoakim M, Neel BG, D’Andrea AD, Frank DA (2001) A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood 97:2230–2237CrossRefPubMed

14.

Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781–787PubMed

15.

Batra S, Perelman N, Luck LR, Shimada H, Malik P (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487CrossRefPubMed

16.

Bauer E, Danhauser-Riedl S, De Riese W, Raab H-R, Sandner S, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R (1992) Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vivo. Onkologie 15:254–258

17.

Berdel WE, Oberberg D, Reufi B, Thiel E (1991) Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 63:5–8PubMed

18.

Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643–651CrossRefPubMed

19.

Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, MacKenzie ET, Petit E (2000) Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30:271–278CrossRefPubMed

20.

Bertram Springborg J, Ma X, Rochat P, Knudsen GM, Amtorp O, Paulson OB, Juhler M, Vidiendal Olsen N (2002) A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 135:823–829PubMed

21.

Bertram Springborg J, Sonne B, Frederiksen HJ, Foldager N, Poulsgaard L, Klausen T, Steen Jorgensen S, Vidiendal Olsen N (2003) Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res 12:143–148CrossRef

22.

Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101:823–828

23.

Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, Brizel DM, Dewhirst MW (2003) Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 63:6162–6165PubMed

24.

Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC (1996) Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50:1255–1261PubMed

25.

Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B (2002) Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 3:145–153CrossRefPubMed

26.

Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526–10531

27.

Brochu E, Lacasse S, Lariviere R, Kingma I, Grose JH, Lebel M (1999) Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10:1440–1446PubMed

28.

Brunet P, Lorec AM, Leonetti F, Roubicek C, Jaber K, Roux F, Berland Y (1994) Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 9:650–654

29.

Buemi M, Grasso G, Corica F, Calapai G, Salpietro FM, Casuscelli T, Sfacteria A, Aloisi C, Alafaci C, Sturiale A, Frisina N, Tomasello F (2000) In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage. Eur J Pharmacol 392:31–34CrossRefPubMed

30.

Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F, Frisina N (2003) The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 62:228–236

31.

Bunworasate U, Amouk H, Mindeman H, O’Loughlin KL, Sait SNJ, Barcos M, Stewart CC, Baer MR (2001) Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98:3492–3494CrossRefPubMed

32.

Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79–85CrossRefPubMed

33.

Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi M (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401:349–356CrossRefPubMed

34.

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802–4806

35.

Campana WM, Myers RR (2001) Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 15:1804–1806PubMed

36.

Canaparo R, Casale F, Muntoni E, Zara GP, Della-Pepa C, Berno E, Pons N, Fornari G, Eandi M (2000) Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 50:146–153CrossRefPubMed

37.

Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43:1010–1014PubMed

38.

Carlini RG, Gupta A, Liapis H, Rothstein M (1995) Endothelin-1 release by erythropoietin involves calcium signaling in endothelial cells. J Cardiovasc Pharmacol 26:889–892PubMed

39.

Carlini RG, Reyes AA, Rothstein M (1995) Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740–745PubMed

40.

Catania MA, Marciano MC, Parisi A, Struriale A, Buemi M, Grasso G, Squadrito F, Caputi AP, Calapai G (2002) Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 437:147–150CrossRefPubMed

41.

Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248–4267PubMed

42.

Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, Brines M (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258–2263

43.

Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM (2002) Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 17:8–12CrossRef

44.

Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5:861–866CrossRefPubMed

45.

Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, Noguchi CT (2000) Production and processing of erythropoietin receptor transcripts brain. Mol Brain Res 81:29–42CrossRefPubMed

46.

Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623–634PubMed

47.

Chong ZZ, Kang JQ, Maiese K (2002) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22:503–514CrossRefPubMed

48.

Chong ZZ, Kang JQ, Maiese K (2003) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106:2973–2979CrossRef

49.

Chong ZZ, Kang JQ, Maiese K (2003) Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 3:141–154PubMed

50.

Chong ZZ, Lin SH, Kang JQ, Maiese K (2003) Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 71:659–669CrossRefPubMed

51.

Cirillo M, Capasso G, DeSanto NG (1993) Relationship between hematocrit and blood pressure: implications for primary hypertension. Nephron 65:505–510PubMed

52.

Dame C, Bartmann P, Wolber E-M, Fahnenstich H, Hofmann D, Fandrey J (2000) Erythropoietin gene expression in different areas of the developing human central nervous system. Dev Brain Res 125:69–74CrossRef

53.

Darling RJ, Kuchibhotla U, Glaesner W, Micanovic R, Witcher DR, Beals JM (2002) Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 41:14524–14531

54.

De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasula SM, Alnemri ES, Testa U, Peschle C (1999) Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401:489–493CrossRefPubMed

55.

Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425PubMed

56.

Digicaylioglu M, Lipton SA (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641–647CrossRefPubMed

57.

Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 92:3717–3720

58.

Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE (2001) Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121:149–152CrossRefPubMed

59.

Dunst J (2000) Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27:4–8PubMed

60.

Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA (2004) Role of apoptosis in reperfusion injury. Cardiovasc Res 61:414–426CrossRefPubMed

61.

Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84:3–10CrossRefPubMed

62.

Ehrenreich H, Hasselblatt M, Dembrowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck H-H, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén A-L (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505PubMed

63.

Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414–421CrossRefPubMed

64.

Emerson MR, Samson FE, Pazdernik TL (2000) Effects of hypoxia preconditioning on expression of metallothionein-1,2 and heme oxygenase-1 before and after kainic acid-induced seizures. Cell Mol Biol 46:619–626

65.

Erbayraktar S, Grasso G, Sfacteria A, Xie Q, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LO, Cerami-Hand C, Wuerth JP, Cerami A, Brines M (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100:6741–6746

66.

Fischer S, Wobben M, Marti HH, Renz D, Schaper W (2002) Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 63:70–80CrossRefPubMed

67.

Fisher JW, Roh BL (1964) Influence of alkylating agents on kidney erythropoietin production. Cancer Res 24:983–988PubMed

68.

Fodinger M, Fritsche-Polanz R, Buchmayer H, Skoupy S, Sengoelge G, Horl WH, Sunder-Plassmann G (2000) Erythropoietin-inducible immediate-early genes in human vascular endothelial cells. J Investig Med 48:137–149PubMed

69.

Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP (2000) Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol 57:13–19CrossRefPubMed

70.

Genc S, Kuralay F, Genc K, Akhisaroglu M, Fadiloglu S, Yorukoglu K, Fadiloglu M, Gure A (2001) Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 298:139–141CrossRefPubMed

71.

Genc S, Akhisaroglu M, Kuralay F, Genc K (2002) Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 321:73–76CrossRefPubMed

72.

Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705–715CrossRefPubMed

73.

Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34:20–26

74.

Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan RS (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234PubMed

75.

Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G, Colowick AB (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268–276CrossRefPubMed

76.

Gogusev J, Zhu DL, Herembert T, Ammarguellat F, Marche P, Drueke T (1994) Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199:977–983CrossRefPubMed

77.

Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M (2002) Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 99:9450–9455

78.

Grasso G (2001) Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci 45:7–14PubMed

79.

Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, Calapai G, De Vico G, Piedimonte G, Salpietro FM, Tomasello F (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99:5627–5631

80.

Grasso G, Passalacqua M, Sfacteria A, Conti A, Morabito A, Mazzullo G, De Vico G, Buemi M, Macri B, Tomasello F (2002) Does administration of recombinant human erythropoietin attenuate the increase of S-100 protein observed in cerebrospinal fluid after experimental subarachnoid hemorrhage? J Neurosurg 96:565–570PubMed

81.

Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ (1999) GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 94:87–96PubMed

82.

Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Remé CE (2002) HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nature Med 8:718–724CrossRefPubMed

83.

Grossi A, Vannucchi AM, Bacci P, Caporale R, Cappelli G, Visconti G, Pagliai G, Ferrini PR (1998) Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. Leuk Res 22:145–151CrossRefPubMed

84.

Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC (1996) Signal transduction of erythropoietin in endothelial cells. Kidney Int 50:481–488PubMed

85.

Hasegawa J, Wagner KF, Karp D, Li D, Shibata J, Heringlake M, Bahlmann L, Depping R, Fandrey J, Schmucker P, Uhlig S (2004) Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. Am J Respir Crit Care Med 169:829–835CrossRefPubMed

86.

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340–1346CrossRefPubMed

87.

Heidenreich S, Rahn KH, Zidek W (1991) Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39:259–265PubMed

88.

Hengartner MO, Horvitz HR (1994) C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76:665–676

89.

Henke M, Laszing R, Rübe C, Schäfer U, Haase K-D, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260CrossRefPubMed

90.

Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM (1997) Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17:2793–2800PubMed

91.

Höckel M, Schlenger K, Mitze M, Schäffer U, Vaupel P (1996) Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6:3–9PubMed

92.

Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326–333CrossRefPubMed

93.

Jelkmann W (1986) Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol 104:139–215PubMed

94.

Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18:555–559PubMed

95.

Jelkmann W (2000) Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 1:11–31PubMed

96.

Jelkmann W (2003) Biochemistry and assays of Epo. In: Jelkmann W (ed) Erythropoietin: molecular biology and clinical use. Graham, Johnson City, pp 35–63

97.

Jelkmann W (2003) Erythropoietin: molecular biology and clinical use. Graham, Johnson City

98.

Jelkmann W (2004) Effects of erythropoietin on brain function. Curr Pharm Biotechnol (in press)

99.

Jumbe NL (2002) Erythropoietic agents as neurotherapeutic agents: what barriers exist? Oncology 16:91–107PubMed

100.

Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM (2002) Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 99:10659–10664

101.

Juul SE (2000) Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 27:527–541PubMed

102.

Juul SE, Harcum J, Li Y, Christensen RD (1997) Erythropoietin is present in the cerebrospinal fluid of neonates. J Pediatr 130:428–430PubMed

103.

Juul SE, Yachnis AT, Christensen RD (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235–249CrossRefPubMed

104.

Juul SE, Stallings SA, Christensen RD (1999) Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 46:543–547PubMed

105.

Juul SE, Yachnis AT, Rojiani AM, Christensen RD (1999) Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 2:148–158CrossRefPubMed

106.

Katoh K, Mizuno K, Hashimoto S, Okazaki K, Asahi K, Kuriki M, Yamada D, Fukuchi S (1994) Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 54:L253–L259CrossRef

107.

Kawakami M, Iwasaki S, Sato K, Takahashi M (2000) Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun 279:293–297

108.

Kayser K, Gabius HJ (1992) Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl Pathol 138:266–270PubMed

109.

Klingmuller U (1997) The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells—signals emanating from the erythropoietin receptor. Eur J Biochem 249:637–647

110.

Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729–738CrossRefPubMed

111.

Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609:29–35CrossRefPubMed

112.

Koshimura K, Murakami A, Sohmiya M, Tanaka I, Katagiri Y (1999) Effects of erythropoietin on neuronal activity. J Neurochem 72:2565–2572CrossRefPubMed

113.

Koury MJ, Bondurant MC (1992) The molecular mechanism of erythropoietin action. Eur J Biochem 210:649–663

114.

Kusano E, Akimoto T, Umino T, Yanagiba S, Inoue M, Ito C, Ando Y, Asano Y (2001) Modulation of endothelin-1-induced cytosolic free calcium mobilization and mitogen-activated protein kinase activation by erythropoietin in vascular smooth muscle cells. Kidney Blood Press Res 24:192–200CrossRefPubMed

115.

Lebel M, Lacasse M, Lariviere R, Kingma I, Grose JH (1998) Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 20:939–951PubMed

116.

Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460CrossRefPubMed

117.

Leyland-Jones B, O’Shoughnessy JA (2003) Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol 30:174–184CrossRefPubMed

118.

Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD (1996) Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 40:376–380PubMed

119.

Liu C, Shen K, Liu Z, Noguchi CT (1997) Regulated human erythropoietin receptor expression in mouse brain. J Biol Chem 272:32395–32400CrossRefPubMed

120.

Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S (2004) Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23:981–990CrossRefPubMed

121.

Macdougall L, Bailon P, Tare N, Pahlke W, Pill J, Brandt M (2003) CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 14:769A

122.

Madan A, Lin C, Wang Z, Curtin PT (2003) Autocrine stimulation by erythropoietin in transgenic mice results in erythroid proliferation without neoplastic transformation. Blood Cells Mol Dis 30:82–89CrossRefPubMed

123.

Marti HH, Bernaudin M (2003) Function of erythropoietin in the brain. In: Jelkmann W (ed) Erythropoietin: molecular biology and clinical use. Graham, Johnson City, pp 195–215

124.

Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8:666–676PubMed

125.

Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, Trentz O, Bauer C (1997) Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 51:416–418PubMed

126.

Marti HH, Bernaudin M, Petit E, Bauer C (2000) Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 15:225–229

127.

Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R (1993) Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268:11208–11216PubMed

128.

Masuda S, Nagao M, Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70:1–6PubMed

129.

Means RT, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639–1647PubMed

130.

Michaelis EK (1998) Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 54:369–415CrossRefPubMed

131.

Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692PubMed

132.

Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 98:5181–5186

133.

Mocanu MM, Baxter GF, Yellon DM (2000) Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol 130:197–200PubMed

134.

Molineux G, Foote M-A, Elliot SG (2003) Erythropoietins and erythropoiesis. Birkhäuser, Basel

135.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100:11612–11617

136.

Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W (1996) Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 24:392–397PubMed

137.

Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105–116CrossRefPubMed

138.

Moritz KM, Lim GB, Wintour EM (1997) Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 273:R1829–R1844PubMed

139.

Mundt D, Berger MR, Bode G (1992) Effect of recombinant human erythropoietin on the growth of human tumor cell lines in vitro. Micro-titertec-tetrazolium assay. Arzneimittelforschung 42:92–95PubMed

140.

Nag S, Takahashi JL, Kilty DW (1997) Role of vascular endothelial growth factor in blood–brain barrier breakdown and angiogenesis in brain trauma. J Neuropathol Exp Neurol 56:912–921

141.

Nagai T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kanamori N, Takayama K, Kinugasa E, Koshikawa S (1995) Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 10:1814–1819PubMed

142.

Nagai T, Akizawa T, Kohjiro S, Koiwa F, Nabeshima K, Niikura K, Kino K, Kanamori N, Kinugasa E, Ideura T (1996) rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int 50:102–107PubMed

143.

Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386–392

144.

Nakamura T, Ebihara I, Shimada N, Koide H (1998) Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients. Am J Med Sci 315:199–201CrossRefPubMed

145.

Neusser M, Tepel M, Zidek W (1993) Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 27:1233–1236PubMed

146.

Ni Z, Wang XQ, Vaziri ND (1998) Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Hypertension 32:724–729PubMed

147.

Nitta K, Uchida K, Kimata N, Honda K, Kobayashi H, Kawashima A, Yumura W, Nihei H (1999) Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur J Pharmacol 373:121–124CrossRefPubMed

148.

Noguchi CT, Chen ZY (2003) Nitric oxide mediates hypoxia-induced erythropoietin receptor expression on neurons. Ann Hematol 82:S112

149.

Noguchi K, Yamashiro S, Matsuzaki T, Sakanashi M, Nakasone J, Miyagi K, Sakanashi M (2001) Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol 133:395–405PubMed

150.

Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 [Suppl 1]:S19–S28PubMed

151.

Oda A, Sawada K-I (2000) Signal transduction in primary cultured human erythroid cells. J Hematother Stem Cell Res 9:417–423CrossRefPubMed

152.

Ohigashi T, Yoshioka K, Fisher JW (1996) Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells. Life Sci 58:421–427

153.

Pagel H, Jelkmann W, Weiss C (1989) Erythropoietin and blood pressure. Horm Metab Res 21:224PubMed

154.

Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M (1998) Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium. J Biol Chem 273:4220–4226CrossRefPubMed

155.

Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999–1007CrossRefPubMed

156.

Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ (2004) Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279:20655–20662CrossRefPubMed

157.

Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35:1681–1691

158.

Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, Meisel A (2003) Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34:1981–1986CrossRefPubMed

159.

Quaschning T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, Hermann M, Slowinski T, Theuring F, Hocher B, Luscher TF, Gassmann M (2003) Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 17:259–261PubMed

160.

Remy I, Wilson IA, Michnick SW (1999) Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990–993CrossRefPubMed

161.

Renzi MJ, Farrell FX, Bittner A, Galindo JE, Morton M, Trinh H, Jolliffe LK (2002) Erythropoietin induces changes in gene expression in PC-12 cells. Mol Brain Res 104:86–95CrossRefPubMed

162.

Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, Nico B, Roncali L, Dammacco F (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636PubMed

163.

Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Gordon MS, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303–2320CrossRefPubMed

164.

Rosti V, Pedrazzoli P, Ponchio L, Zibera C, Novella A, Lucotti C, Della-Cuna GR, Cazzola M (1993) Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78:208–212PubMed

165.

Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R (1998) Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253:26–32CrossRefPubMed

166.

Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635–4640

167.

Sasaki R (2003) Pleiotropic functions of erythropoietin. Intern Med 42:142–149PubMed

168.

Sasaki R, Masuda S, Nagao M (2000) Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 64:1775–1793

169.

Sawyer ST (1989) The two proteins of the erythropoietin receptor are structurally similar. J Biol Chem 264:13343–13347PubMed

170.

Sekiguchi Y, Kikuchi S, Myers RR, Campana WM (2004) ISSLS prize winner: erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 28:2577–2584

171.

Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, Jansen B (2000) Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10:421–426CrossRefPubMed

172.

Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D (2003) Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297–307CrossRefPubMed

173.

Shingo T, Sorokan ST, Shimazaki T, Weiss S (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21:9733–9743PubMed

174.

Simon RP, Niiro M, Gwinn R (1993) Prior ischemic stress protects against experimental stroke. Neurosci Lett 163:135–137CrossRefPubMed

175.

Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044–4049

176.

Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H (2001) Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl) 101:271–276

177.

Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548CrossRefPubMed

178.

Sterin-Borda L, Barcelo AC, Bozzini CE (2003) Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol 121:180–186PubMed

179.

Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, Wold B, McKay C (2000) Enhanced proliferation, survival, and dopaminergic differentation of CNS precursors in lowered oxygen. J Neurosci 20:7377–7383PubMed

180.

Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H (2002) Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 44:391–403CrossRefPubMed

181.

Supino-Rosin L, Yoshimura A, Altaratz H, Neumann D (1999) A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem 263:410–419

182.

Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M (2002) Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100:2279–2288CrossRefPubMed

183.

Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511–516CrossRefPubMed

184.

Takeshita A, Shinjo K, Naito K, Ohnishi K, Higuchi M, Ohno R (2002) Erythropoietin receptor in myelodysplastic syndrome and leukemia. Leuk Lymphoma 43:261–264CrossRefPubMed

185.

Tauchi T, Feng GS, Shen R, Hoatlin M, Bagby GCJr, Kabat D, Lu L, Broxmeyer HE (1995) Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 270:5631–5635CrossRefPubMed

186.

Teicher BA (1995) Physiologic mechnaisms of therapeutic resistance. Drug Resistance Clin Oncol Hematol 9:475–506

187.

Thomas G (2001) The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28:60–65CrossRef

188.

Tojo A, Doumoto M, Oka K, Numabe A, Kimura K, Yagi S (1996) Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Physiol 270:R744–R748PubMed

189.

Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308:990–994

190.

Tsukahara H, Hiraoka M, Hori C, Hata I, Okada T, Gejyo F, Sudo M (1997) Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 57:487–493PubMed

191.

Vannucci RC, Towfighi J, Vannucci SJ (1998) Hypoxic preconditioning and hypoxic-ischemic brain damage in the immature rat: pathologic and metabolic correlates. J Neurochem 71:1215–1220PubMed

192.

Vaupel P, Mayer A (2004) Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363:992CrossRef

193.

Vaupel P, Mayer A , Briest S, Hockel M (2003) Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 63:7634-7637PubMed

194.

Vaupel P, Mayer A , Hockel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335-354CrossRefPubMed

195.

Vaupel P, Thews O, Kelleher DK, Hoeckel M (1998) Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 174 [Suppl 4]:6–12PubMed

196.

Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C, Mayeux P (2000) Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 275:18375–18381CrossRefPubMed

197.

Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971–975CrossRefPubMed

198.

Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkmann W, Fandrey J (1997) Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 10:289–296CrossRefPubMed

199.

Wagner K, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U, Schramm U, Jelkmann W, Gassmann M, Fandrey J (2001) Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97:536–542CrossRefPubMed

200.

Wald MR, Borda ES, Sterin-Borda L (1996) Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 167:461–468CrossRefPubMed

201.

Wang XQ, Vaziri ND (1999) Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33:894–899PubMed

202.

Wang CH, Liang CL, Huang LT, Liu JK, Hung PH, Sun A, Hung KS (2004) Single intravenous injection of naked plasma DNA encoding erythropoietin provides neuroprotection in hypoxia–ischemia rats. Biochem Biophys Res Commun 314:1064–1071CrossRefPubMed

203.

Wen TC, Sadamoto Y, Tanaka I, Zhu PX, Nakata K, Ma YJ, Hata R, Sakanaka M (2002) Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67:795–803CrossRefPubMed

204.

Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647–657CrossRefPubMed

205.

Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E (2002) Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88:150–159PubMed

206.

Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ (1993) Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 44:430–435PubMed

207.

Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74:227–236CrossRefPubMed

208.

Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ (1999) Signal transduction in the erythropoietin receptor system. Exp Cell Res 253:143–156CrossRefPubMed

209.

Wolff M, Jelkmann W (1993) Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 66:27–31PubMed

210.

Wollman Y, Westphal G, Blum M, Simantov R, Blumberg S, Peer G, Chernihovsky T, Friedrich E, Iaina A (1996) The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci 59:315–322

211.

Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML (1999) Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126:3597–3605PubMed

212.

Wu XC, Johns EJ, Richards NT (1999) Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin Sci (Lond) 97:413–419

213.

Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y (1996) Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239:494–500

214.

Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R (1998) Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273:25381–25387CrossRefPubMed

215.

Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y (2001) Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836–843CrossRefPubMed

216.

Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23:1797–1805CrossRefPubMed

217.

Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021–1029CrossRefPubMed

218.

Yi T, Zhang J, Miura O, Ihle JN (1995) Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 85:87–95PubMed

219.

Yoshimura A, Misawa H (1998) Physiology and function of the erythropoietin receptor. Curr Opin Hematol 5:171–176PubMed

Title: Beneficial and ominous aspects of the pleiotropic action of erythropoietin
Authors: Wolfgang Jelkmann
Klaus Wagner
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 11/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-004-0911-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Angioimmunoblastic T-cell lymphoma with renal involvement: a case report of direct bilateral kidney invasion by lymphoma cells

Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes

Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study

Antiproliferation effects of oridonin on HL-60 cells

Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials